drugset / Trial / NCT00291954

Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination

NCT00291954

Phase 3 Completed 257 enrolled Henogen GlaxoSmithKline · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

Hepatitis B prevention in non-responders uraemic patients is currently based on both HBsAg surveillance and the isolation from HBsAg carriers. A more immunogenic vaccine would be a benefit for this population.

Timeline

Start
2006-03
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HB-AS02V Vaccine 20 ug
Comparator HBVAXPRO Vaccine 40 ug